Co-founder, CEO

David Du, Ph.D.

He received his PhD in Biochemistry from the University of Florida in the US. He also did his postdoctoral research at the National College of Medicine. Former FDA reviewing officer, and senior executives of several pharmaceutical MNCs. Fully familiar with the FDA and global drug development process, including manufacturing, quality management, clinical design, drug product marketing application, and global post-marketing management of drug products. Dr. Du used to be a CMC reviewer of FDA, responsible for IND and BLA review of biologics. Thereafter, he worked at Aventis-Pasteur/Sanofi, Wyeth/Pfizer, Novartis, BMS, NPS and other multinational pharmaceutical companies. With more than 20 years of experience in the pharmaceutical industry, he has managed to obtain 4 BLAs from FDA, 2 biological approvals in the EU and Canada, as well as numerous IND clearances in the US, China, the EU, and other countries, involving various types of products such as large and small molecules, cells and genes, oncolytic viruses and drug device combinations. He also has experience in managing marketed drugs in more than 30 countries.

Co-founder, CMO

Charles Lee, M.D., Ph.D.

He graduated from Xi 'an Jiaotong University School of Medicine and received his Master's degree in hospital Administration and doctor of Public Health degree from the University of Alabama Birmingham, USA. He did three years of residency at the University of Chicago Medical Center and obtained the American Physician license and the American Clinical Pathology Specialist certification. He used to be a senior medical reviewer of THE US Food and Drug Administration (FDA), and was the first overseas Chinese to enter FDA's clinical review as a doctor. Dr. Charles Lee has extensive experience in phase I-IV global clinical trials in oncology, immunotherapy, anti-inflammatory, gastrointestinal diseases, and gynecological diseases. He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing overall solutions for global drug development, regulatory registration, clinical strategy and risk management.

Director of AI Bioinformatics

Bill Wang, Ph.D.

Graduated from Beijing Normal University, received his Ph.D. in Biology from Uppsala University, and postdoctoral fellow at Kanarinska Institutet, Sweden; He was a former Director of the Bioinformatics Centre at the University of Melbourne, and is a scientist with many years of experience in bioinformatics engineering and genomics research.

VP, Clinical Operation

Patrick McGrath, Ph.D

PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.

Senior Director, CMC and Regulatory Affairs

Shanshan Li, Ph.D.

Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.

CBO

Kevin Wang

Graduated from the University of Miami with an MBA and a Master of Biostatistics. He has more than 15 years of experience in the pharmaceutical industry and more than 5 years of business development experience. He has worked in US-listed pharmaceutical companies and pharmaceutical consulting companies for many years, and has worked in AOB and Humphrey Pharmaceutical Consulting, serving as Deputy General Manager of Business Development and Assistant to the president. He is familiar with the daily operation of innovative pharmaceutical companies and has extensive experience in business cooperation, patent planning and technology transfer of pharmaceutical projects.

Senior Director of Public Affairs

James Diao

Graduated from Newcastle University Business School; and received a MSc in Project Management from the University of Manchester; with PRINCE2 certified for project management by UK government. He started his healthcare career at Omnicom Health Group AP and served as Executive Assistant; he provided market consulting services for several MNCs including MSD, Pfizer and Novartis. Prior to joining Evergreen, he was the Vice President of Continental Capital and has abundant experience in the market research and investment field of the pharmaceutical industry.

Business Development Director

Minghan Cui

Master of Pharmaceutical Engineering, South China Agricultural University; Used to be the marketing manager of clinical Coordination Department of Hengrui Pharmaceutical. Pfizer China Cardiovascular Group SMICS; Researcher of Pharmaceutical Research Institute of Guangyao Baiyunshan Pharmaceutical General Factory.

BD Associate Director

Bertram Cai

Master of Biochemistry and Molecular Biology, Anhui University. Worked for Pfizer China cardiovascular and anti-inflammatory and analgesic unit as SMICS; SMICS for the full product of Bo Ruilin Group.